Sugi Predict

Sugi Predict / Compounds / SCHEMBL6433972

SCHEMBL6433972

SCHEMBL6433972

COc1ccc(NC=C2C(=O)OC(C)(C)OC2=O)cc1OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ CASP1 P29466 1/20 0.52
▸ CASP7 P55210 1/20 0.52
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ RAB9A P51151 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ SMPD1 P17405 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ CTSV O60911 1/20 0.46
▸ CTSL P07711 1/20 0.46
▸ KMT2A Q03164 2/20 0.45
▸ SIRT2 Q8IXJ6 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ ALOX12 P18054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25260320 0.96 ALDH1A1 (0.54) ALDH1A1HSD17B10MAPK1CASP1CASP7
SCHEMBL17181501 0.88 ALDH1A1 (0.59) ALDH1A1HSD17B10MAPK1CASP1CASP7
SCHEMBL12663537 0.88 ALDH1A1 (0.54) ALDH1A1HSD17B10MAPK1CASP1CASP7
SCHEMBL374339 0.86 ALDH1A1 (0.67) ALDH1A1HSD17B10MAPK1CASP1CASP7
SCHEMBL1890489 0.85 ALDH1A1 (0.49) ALDH1A1HSD17B10MAPK1CASP1CASP7
SCHEMBL6431150 0.85 ALDH1A1 (0.51) ALDH1A1HSD17B10MAPK1CASP1CASP7
SCHEMBL5649656 0.84 ALDH1A1 (0.56) ALDH1A1HSD17B10MAPK1CASP1CASP7
SCHEMBL12003807 0.81 ALDH1A1 (0.67) ALDH1A1HSD17B10MAPK1CYP1A2CYP3A4
SCHEMBL17781001 0.80 ALDH1A1 (0.44) ALDH1A1SMPD1HDAC1HDAC8HDAC6
SCHEMBL21588777 0.79 ALDH1A1 (0.47) ALDH1A1HSD17B10MAPK1CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200392110-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2020-12-17 — — US disclosed
EP-3415501-B9 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2020-12-02 — — EP disclosed
US-10676462-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2020-06-09 — — US disclosed
EP-3415501-B1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO (JP) 2020-04-08 — — EP disclosed
US-10501442-B2 Quinoline derivative ONO PHARMACEUTICALS CO., LTD. (JP) 2019-12-10 — — US disclosed
US-20190135785-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2019-05-09 — — US disclosed
US-10208022-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2019-02-19 — — US disclosed
EP-3415501-A1 QUINOLINE DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2018-12-19 — — EP disclosed
US-9994549-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2018-06-12 — — US disclosed
WO-2018064852-A1 NAPHTHYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF 南京纳丁菲医药科技有限公司 2018-04-12 — — WO disclosed
US-20180099962-A1 NAPHTHYRIDINE COMPOUNDS, MEDICAL COMBINATIONS AND USE THEREOF NANJING NATINEFY PHARMATECH CO., LTD. (CN) 2018-04-12 — — US disclosed
US-9938274-B1 Naphthyridine compounds, medical combinations and use thereof NANJING NATINEFY PHARMATECH CO., LTD. (CN) 2018-04-10 — — US disclosed
US-20170088542-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2017-03-30 — — US disclosed
US-9573935-B2 Quinoline derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2017-02-21 — — US disclosed
US-20160168121-A1 QUINOLINE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2016-06-16 — — US disclosed
WO-2012171487-A1 ARYLOXY QUINOLINES DERIVATIVES AND THE TREATING USE THEREOF 天津隆博基因药物科技有限公司 (CN) 2012-12-20 — — WO disclosed
EP-0929526-B1 QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF ASTRAZENECA AB (SE) 2005-07-27 — — EP disclosed
US-6809097-B1 ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY ZENECA LIMITED (GB) 2004-10-26 — — US disclosed
EP-0929526-A1 QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF ZENECA LIMITED (GB) 1999-07-21 — — EP disclosed
WO-1998013350-A1 QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF ZENECA LIMITED (GB) 1998-04-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099962-A1 NAPHTHYRIDINE COMPOUNDS, MEDICAL COMBINATIONS AND USE THEREOF NPM1, NEK4, NME1 ALDH1A1 3003/4885HSD17B10 3174/4885MAPK1 108/4885
US-20200392110-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 ALDH1A1 3779/4885HSD17B10 4526/4885MAPK1 260/4885
US-10501442-B2 Quinoline derivative FLT3, AXL, ERBB2 ALDH1A1 3779/4885HSD17B10 4526/4885MAPK1 260/4885
US-10208022-B2 Quinoline derivative FLT3, AXL, ERBB2 ALDH1A1 3779/4885HSD17B10 4526/4885MAPK1 260/4885
US-20160168121-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 ALDH1A1 3490/4885HSD17B10 4396/4885MAPK1 193/4885
US-20170088542-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 ALDH1A1 3779/4885HSD17B10 4526/4885MAPK1 260/4885
US-10676462-B2 Quinoline derivative FLT3, AXL, ERBB2 ALDH1A1 3779/4885HSD17B10 4526/4885MAPK1 260/4885
US-20190135785-A1 QUINOLINE DERIVATIVE FLT3, AXL, ERBB2 ALDH1A1 3779/4885HSD17B10 4526/4885MAPK1 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.